Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release Tablets (NAL ER) for the Treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF)
Conditions
Interventions
NAL ER
Placebo
+2 more
Locations
59
Australia
Eastern Health-Box Hill Hospital
Box Hill, Australia
Concord Repatriation General Hospital
Concord, Australia
Austin Hospital
Heidelberg, Australia
Respiratory Clinical Trials Pty Ltd
Kent Town, Australia
TrialsWest Pty Ltd
Spearwood, Australia
Westmead Hospital
Westmead, Australia
Start Date
February 6, 2024
Primary Completion Date
April 24, 2025
Completion Date
April 24, 2025
Last Updated
June 27, 2025
NCT06238622
NCT07299695
NCT07466420
NCT06241560
NCT07407543
NCT05989698
Lead Sponsor
Trevi Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions